Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-744-1340
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.05 million
Profitability
Miscellaneous
Employees76
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions
What is Syros Pharmaceuticals' stock symbol?
Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."
How were Syros Pharmaceuticals' earnings last quarter?
Syros Pharmaceuticals Inc (NASDAQ:SYRS) announced its quarterly earnings results on Thursday, August, 1st. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by $0.06. The firm earned $0.46 million during the quarter, compared to the consensus estimate of $0.42 million. Syros Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 3,137.55%. View Syros Pharmaceuticals' Earnings History.
When is Syros Pharmaceuticals' next earnings date?
What price target have analysts set for SYRS?
5 equities research analysts have issued 12-month price targets for Syros Pharmaceuticals' shares. Their predictions range from $10.00 to $24.00. On average, they expect Syros Pharmaceuticals' stock price to reach $15.8333 in the next year. This suggests a possible upside of 41.4% from the stock's current price. View Analyst Price Targets for Syros Pharmaceuticals.
What is the consensus analysts' recommendation for Syros Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syros Pharmaceuticals.
What are Wall Street analysts saying about Syros Pharmaceuticals stock?
Here are some recent quotes from research analysts about Syros Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. " (9/18/2019)
- 2. HC Wainwright analysts commented, "Our price target of $10/share ($4.0 from tamibarotene + $3.4 from platform + $2.6 in cash) is based on a discounted cash flow analysis (2019-2027) using a 12% discount rate and 1% growth rate, in line with the expected discount and growth parameters of a development-stage oncology company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition, and pricing." (3/8/2019)
Has Syros Pharmaceuticals been receiving favorable news coverage?
News stories about SYRS stock have been trending somewhat negative on Saturday, according to InfoTrie. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Syros Pharmaceuticals earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Syros Pharmaceuticals.
Are investors shorting Syros Pharmaceuticals?
Syros Pharmaceuticals saw a decline in short interest during the month of August. As of August 15th, there was short interest totalling 2,717,900 shares, a decline of 19.7% from the July 15th total of 3,386,500 shares. Based on an average daily trading volume, of 181,400 shares, the days-to-cover ratio is presently 15.0 days. Currently, 12.6% of the shares of the stock are sold short. View Syros Pharmaceuticals' Current Options Chain.
Who are some of Syros Pharmaceuticals' key competitors?
Some companies that are related to Syros Pharmaceuticals include Ligand Pharmaceuticals (LGND), Deciphera Pharmaceuticals (DCPH), Zogenix (ZGNX), Eidos Therapeutics (EIDX), Uniqure (QURE), Insmed (INSM), Prestige Consumer Healthcare (PBH), Tricida (TCDA), Heron Therapeutics (HRTX), Nabriva Therapeutics (NBRV), Apellis Pharmaceuticals (APLS), Corcept Therapeutics (CORT), Alder Biopharmaceuticals (ALDR), Pacira Biosciences (PCRX) and Madrigal Pharmaceuticals (MDGL).
What other stocks do shareholders of Syros Pharmaceuticals own?
Who are Syros Pharmaceuticals' key executives?
Syros Pharmaceuticals' management team includes the folowing people:
- Dr. Nancy A. Simonian, Pres, CEO & Director (Age 58)
- Dr. Richard A. Young, Scientific Founder, Member of Scientific Advisory Board & Director (Age 65)
- Dr. David A. Roth, Chief Medical Officer (Age 56)
- Dr. Jeremy P. Springhorn, Chief Bus. Officer (Age 57)
- Dr. Nathanael S. Gray, Scientific Founder & Member of Scientific Advisory Board
When did Syros Pharmaceuticals IPO?
(SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Who are Syros Pharmaceuticals' major shareholders?
Syros Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (8.94%), Nikko Asset Management Americas Inc. (7.04%), BlackRock Inc. (6.28%), Vanguard Group Inc. (4.16%), Samsara BioCapital LLC (4.07%) and Sumitomo Mitsui Trust Holdings Inc. (3.75%). Company insiders that own Syros Pharmaceuticals stock include Colleen Elizabeth Desimone, Jeremy P Springhorn, Richard A Young, Srinivas Akkaraju and Venture Fund Vii LP Arch. View Institutional Ownership Trends for Syros Pharmaceuticals.
Which institutional investors are selling Syros Pharmaceuticals stock?
SYRS stock was sold by a variety of institutional investors in the last quarter, including Connor Clark & Lunn Investment Management Ltd., Candriam Luxembourg S.C.A., GSA Capital Partners LLP, D. E. Shaw & Co. Inc., Price T Rowe Associates Inc. MD, BNP Paribas Arbitrage SA and Wells Fargo & Company MN. Company insiders that have sold Syros Pharmaceuticals company stock in the last year include Richard A Young and Venture Fund Vii LP Arch. View Insider Buying and Selling for Syros Pharmaceuticals.
Which institutional investors are buying Syros Pharmaceuticals stock?
SYRS stock was acquired by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Vanguard Group Inc., ARK Investment Management LLC, Samsara BioCapital LLC, BlackRock Inc., EcoR1 Capital LLC and Charles Schwab Investment Management Inc.. Company insiders that have bought Syros Pharmaceuticals stock in the last two years include Jeremy P Springhorn and Srinivas Akkaraju. View Insider Buying and Selling for Syros Pharmaceuticals.
How do I buy shares of Syros Pharmaceuticals?
Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Syros Pharmaceuticals' stock price today?
One share of SYRS stock can currently be purchased for approximately $11.20.
How big of a company is Syros Pharmaceuticals?
Syros Pharmaceuticals has a market capitalization of $475.33 million and generates $2.05 million in revenue each year. The company earns $-62,280,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Syros Pharmaceuticals employs 76 workers across the globe.View Additional Information About Syros Pharmaceuticals.
What is Syros Pharmaceuticals' official website?
How can I contact Syros Pharmaceuticals?
Syros Pharmaceuticals' mailing address is 620 Memorial Drive Suite 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]
MarketBeat Community Rating for Syros Pharmaceuticals (NASDAQ SYRS)
MarketBeat's community ratings are surveys of what our community members think about Syros Pharmaceuticals and other stocks. Vote "Outperform" if you believe SYRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
